Health Canada approves Xience V
This article was originally published in Clinica
Executive Summary
Abbott's everolimus-eluting Xience V stent has gained Canadian approval for the treatment of coronary artery disease (CAD). Abbott will launch the device in Canada immediately on both over-the-wire and rapid exchange delivery systems. Cardiovascular disease is the leading cause of death in Canada, and 54% of all cardiovascular deaths are due to CAD.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.